Moderna's mRNA Flu Vaccine Shows Promising Results in Phase 3 Trial: Could Revolutionize Flu Prevention
Flu shots vary in effectiveness each year, sometimes reducing the risk of illness by only 20% to 30%. Messenger RNA (mRNA) technology is considered a promising advancement in flu vaccine development due to its ability to be quickly updated to match circulating strains. Moderna's mRNA flu vaccine showed better protection against illness compared to the standard flu shot in a Phase 3 clinical trial, performing about 27% better. This positive outcome could enhance the vaccine's chances of approval after the FDA rejected Moderna's initial submission earlier this year.
The trial, funded by Moderna, involved over 40,000 adults aged 50 and above who received either the mRNA vaccine or one of four standard flu shots during the 2024–2025 flu season. The results indicated that fewer people in the mRNA flu vaccine group fell ill compared to the standard flu shot group. Although the mRNA group experienced more side effects like fatigue, headache, and arm pain, these reactions were mild and short-lived, similar to traditional flu shot side effects.
An mRNA flu shot could revolutionize flu prevention by allowing for faster vaccine development. Traditional flu shots take months to produce, potentially resulting in mismatched strains. In contrast, mRNA technology enables quicker vaccine production, providing health officials with more flexibility to adapt to changing circulating strains. The FDA is expected to make a decision on Moderna's mRNA flu shot by August 5, with the drugmaker anticipating approval.
Despite concerns raised by anti-vaccine activists, including Health Secretary Robert F. Kennedy, about mRNA vaccines, health experts emphasize the importance of evaluating all vaccine technologies fairly. Dr. Peter Hotez, a vaccine development expert, highlights the need to keep multiple vaccine technologies available to effectively protect the population against emerging pathogens. The FDA's review of Moderna's mRNA flu vaccine will play a crucial role in determining its approval and potential impact on flu prevention efforts.